The Industry

March 2010
Pharmaceutical Representative;Mar2010, Vol. 40 Issue 3, p7
The article offers updates related to the pharmaceutical industry across the globe. Pfizer Inc. has increased its revenue despite losing patent exclusivity of the cholesterol drug Lipitor. Novartis AG has announced that Joe Jimenez will replace Daniel Vasella as chief executive officer (CEO). Sanofi-Aventis has partnered with KaloBios Pharmaceutical to develop treatment for Pseudomonas aeruginosa infections.


Related Articles

  • G&P Foundation for Cancer Research Presents Dr. Daniel Vasella, Novartis CEO, With Top Industry Leader Award.  // Ascribe Newswire: Medicine;11/13/2000, p24 

    The article reports on Daniel Vasella, M.D., Chairman and CEO for Novartis AG, one of the world's largest pharmaceutical companies, who will be honored with the G&P Foundation for Cancer Research's Distinguished Industry Leadership Award. Novartis has made significant contributions to the...

  • DANIEL VASELLA. Chandler, Clay; Guyon, Janet; Hjelt, Paola; Murphy, Cait; Tomlinson, Richard // Fortune International (Europe);8/11/2003, Vol. 148 Issue 3, p39 

    Last year Daniel Vasella of Novartis received a compensation package totaling $14.5 million, making him one of Europe's highest-paid CEOs. But unlike in other high-profile cases, few Novartis shareholders are questioning his value. Formed by the 1996 merger of Sandoz and Ciba-Geigy, Novartis has...

  • Novartis -- Italian style.  // European Pharmaceutical Executive;Oct2007, p13 

    The article reports that Daniel Vasella, chairman of Novartis AG, has announced that the company is set to invest in research and innovation in Italy. The company is planning to split the €600 million investment between its existing vaccine research center in Siena and in the creation of a...

  • Evolution of value. Koberstein, Wayne // Pharmaceutical Executive;Jul98, Vol. 18 Issue 7, p40 

    Focuses on Novartis, a pharmaceutical company, and its head officer, Daniel Vasella. Responsibilities of Vasella; Moves that strengthened the portfolio of Novartis; Integration of research and development and marketing in the company; Vasella's description of some products released by Novartis.

  • the book on. Armstrong, Walter // Pharmaceutical Executive;Oct2009, Vol. 29 Issue 10, p46 

    The article profiles Daniel Vasella, the chief executive officer (CEO) of Novartis AG . It discusses several contributions of Vasella in the development of the firm. It mentions that the CEO has established the Swiss firm as the world's fastest-growing pharmaceutical industry and became a...

  • Novartis targeted by animal-rights extremists.  // Nature;8/13/2009, Vol. 460 Issue 7257, p791 

    The article reports on the attacks made by the militant animal-rights activists to the Alpine holiday home of Daniel Vasella, head of the pharmaceutical company Novartis AG in Switzerland, last August 3, 2009. According to Novartis, their employees had at least ten recent attacks including the...

  • COMPANY SPOTLIGHT - Novartis AG.  // PharmaWatch: Cancer;September 2003, Vol. 2 Issue 9, p24 

    Features the Swiss healthcare and drug company Novartis AG. Financial performance for 2002; Research efforts for health and well-being; Description of major products and services; Profiles on key executives Daniel Vasella and Raymond Breu; Focus on the cardiovascular and cancer markets.

  • Daniel Vasella. Hughes, Bethan // Nature Reviews Drug Discovery;Feb2010, Vol. 9 Issue 2, p98 

    An interview with Daniel Vasella, chairman and chief executive officer (CEO) at Novartis AG in Basel, Switzerland, is presented. When asked about the most essential factors for the success of research and development (R&D), he mentions on people, openness of the organization, and investment. He...

  • The Right Prescription? Vasella, Daniel // Newsweek (Atlantic Edition);2/21/2005 (Atlantic Edition), Vol. 145 Issue 8, p60 

    Presents an interview with the medical doctor who runs the Swiss pharmaceutical group Novartis, Daniel Vasella. Comments on the financial incentive to producing drugs, and whether or not drug companies focus on rich-country diseases; Suggestion that governments create financial incentives to get...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics